Pharming Group N.V. Files Form 6-K with Press Release

Ticker: PHAR · Form: 6-K · Filed: 2024-05-15T00:00:00.000Z

Sentiment: neutral

Topics: filing, press-release, pharmaceutical

TL;DR

Pharming Group N.V. dropped a 6-K filing with a press release on May 15, 2024. Check it out.

AI Summary

Pharming Group N.V. filed a Form 6-K on May 15, 2024, to furnish a press release dated the same day. The press release, filed as Exhibit 99.1, likely contains important updates or announcements from the company. Pharming Group N.V. is a pharmaceutical company incorporated in the Netherlands.

Why It Matters

This filing indicates that Pharming Group N.V. is providing new information to investors, which could impact the company's stock price or future performance.

Risk Assessment

Risk Level: low — This filing is a routine report of a foreign private issuer and does not appear to contain significant negative or positive financial news on its own.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to furnish a press release dated May 15, 2024, as Exhibit 99.1.

What is the SEC file number for Pharming Group N.V.?

The SEC file number for Pharming Group N.V. is 001-39822.

What is the Standard Industrial Classification code for Pharming Group N.V.?

The Standard Industrial Classification code for Pharming Group N.V. is 2834, which corresponds to Pharmaceutical Preparations.

Where is Pharming Group N.V. headquartered?

Pharming Group N.V. is headquartered in Leiden, The Netherlands.

What type of company is Pharming Group N.V.?

Pharming Group N.V. is a pharmaceutical company.

From the Filing

0001828316-24-000022.txt : 20240515 0001828316-24-000022.hdr.sgml : 20240515 20240515115235 ACCESSION NUMBER: 0001828316-24-000022 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240515 FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 24948482 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharmingearlyconvertiblebo.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated May 15, 2024. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Sijmen de Vries Name: Sijmen de Vries Title: CEO Date: May 15, 2024 THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER. THIS NOTICE IS NOT FOR DISTRIBUTION IN OR TO ANY PERSON LOCATED IN ANY JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 Leiden, the Netherlands, 15 May 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces today that it is exercising its clean-up call option with respect to its outstanding €125 million 3.00% convertible bonds due 2025 (ISIN: XS2105716554) (the "2025 Bonds") in line with Condition 4.1 of the terms and conditions (the "Conditions") of the 2025 Bonds. Currently €1.9 million in aggregate principal amount of the 2025 Bonds remain outstanding which represent less than 15% of the aggregate principal amount of the 2025 Bonds originally issued, after €123.1 million in aggregate principal amount of the 2025 Bonds were repurchased by the Company on 26 April 2024. The remainder of the 2025 Bonds will be redeemed on 18 June 2024 (the "Redemption Date") at 100% of the principal amount per 2025 Bond (equal to €100,000 per principal amount of €100,000 per 2025 Bond). The Compan

View on Read The Filing